Barclays analyst Charles Pitman-King lowered the firm’s price target on Argenx (ARGX) to EUR 650 from EUR 710 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Receives Positive CHMP Opinion for VYVGART in CIDP Treatment
- Argenx announces CHMP opinion recommending approval of Vyvgart 1000mg
- Argenx Se’s Revenue Growth Potential Boosted by Vyvgart Hytrulo’s Market Impact and Increased Treatment Cycles
- Argenx price target lowered to EUR 680 from EUR 736 at BofA
- Argenx price target raised to $796 from $681 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue